JAMA Netw Open:公众认为哪些群体应优先获得新冠疫苗?

2021-04-14 网络 网络

目前美国各地已开始大规模接种新冠疫苗,

目前美国各地已开始大规模接种新冠疫苗,疾病控制和预防中心(CDC免疫实践咨询委员会(ACIP)与国家科学院、工程院和,医学部(NASEM)关于如何公平分配新冠疫苗已经构建了初步框架:首先卫生保健人员和长期护理机构居民接受初始剂量(1a期),其次是75岁以上的人和一线工作者(1b期),最后是65-74岁以及处于高风险医疗工作条件工作人员(1c期)。

随着新冠疫苗接种工作的进行,政策制定者面临着许多关于如何分配疫苗的开放性问题,比如基本工作人员、健康老年人和有高风险医疗条件的人的相对优先顺序是什么?是否应优先考虑受新冠病毒影响过大的社会经济弱势群体?公众的参与有助于解答这样的问题,也有助于确定公众价值观和拟议优先方案之间的差距。先前的调查研究了在大流行中稀缺资源分配的偏好,但很少有研究专门关注新冠疫苗分配。为了弥补这一空缺,近日有研究人员调查了两个有代表性的美国成年人样本,以了解新冠疫苗分配的优先顺序。该研究结果发表在JAMA Netw Open期刊上。

该研究主要是建立在先前的调查基础上。首先,要求调查对象对优先群体进行排序,这更准确地反映了疫苗稀缺条件下的疫苗分配。其次,对某些基本工作人员进行分类,如教师、餐馆员工和杂货店员工。第三,调查人们对不同的分配标准的态度。

本调查研究共有4735人参与,调查对象将医护人员和有严重健康问题的任何年龄段的成年人列为4个最高优先级组。所有政治派别的调查对象都同意优先考虑黑人、西班牙裔、美洲原住民和其他受新冠病毒影响较大的社区人群。在这两项调查中,对比年轻的调查对象,年龄较大的调查对象更不可能将65岁及以上的健康成年人列为4个最优先人群。调查对象认为,优先考虑的4个最重要因素是预防新冠病毒的传播、预防最多的死亡、预防长期并发症和保护一线工人

总之,美国成年人普遍同意美国国家科学院、工程院和医学院制定的优先顺序框架。调查对象支持优先考虑受新冠病毒影响过大的社区,年龄较大的调查对象比年轻的调查对象更不可能支持65岁以上的健康人优先接种疫苗。这更提醒决策者要对新冠疫苗分发计划持谨慎态度。

这两项针对美国成年人的调查结果表明,美国公众同意NASEM和ACIP关于新冠病毒疫苗按阶段分发计划的核心内容。他们还支持优先考虑受疫情影响较严重的社区,包括有色人种社区。在基于年龄的优先事项方面,调查对象与政府机构持有不同意见,调查对象强烈支持优先考虑教师和托儿工作者特别值得注意的是,较年长的调查对象较少支持优先考虑65岁以上的健康人群,而较多的调查对象选择优先考虑年轻和中年人群接种疫苗。

这些发现表明,相比单一按照年龄因素进行疫苗分配工作,公众更支持多种价值因素共同作用的优先排序方法。决策者应在现有努力的基础上再接再厉,例如积极主动地向受影响大的社区和工作场所投入疫苗资源,以实现既迅速又符合公众价值观的疫苗分发工作。

参考文献:Persad G, Emanuel EJ, Sangenito S, Glickman A, Phillips S, Largent EA. Public Perspectives on COVID-19 Vaccine Prioritization. JAMA Netw Open. 2021;4(4):e217943. doi:10.1001/jamanetworkopen.2021.7943

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1734350, encodeId=bed41e343504c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jan 11 13:18:51 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728908, encodeId=d3441e2890865, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 08 20:18:51 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717067, encodeId=a8f51e170670f, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Mar 22 13:18:51 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958281, encodeId=34dc95828114, content=毫无疑问,出国的,医护人员 , beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ZJYYY7, createdTime=Mon Apr 19 11:59:08 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029380, encodeId=a95a1029380e0, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036573, encodeId=668610365e315, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2022-01-11 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1734350, encodeId=bed41e343504c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jan 11 13:18:51 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728908, encodeId=d3441e2890865, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 08 20:18:51 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717067, encodeId=a8f51e170670f, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Mar 22 13:18:51 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958281, encodeId=34dc95828114, content=毫无疑问,出国的,医护人员 , beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ZJYYY7, createdTime=Mon Apr 19 11:59:08 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029380, encodeId=a95a1029380e0, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036573, encodeId=668610365e315, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-05-08 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1734350, encodeId=bed41e343504c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jan 11 13:18:51 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728908, encodeId=d3441e2890865, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 08 20:18:51 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717067, encodeId=a8f51e170670f, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Mar 22 13:18:51 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958281, encodeId=34dc95828114, content=毫无疑问,出国的,医护人员 , beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ZJYYY7, createdTime=Mon Apr 19 11:59:08 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029380, encodeId=a95a1029380e0, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036573, encodeId=668610365e315, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2022-03-22 xjy13
  4. [GetPortalCommentsPageByObjectIdResponse(id=1734350, encodeId=bed41e343504c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jan 11 13:18:51 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728908, encodeId=d3441e2890865, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 08 20:18:51 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717067, encodeId=a8f51e170670f, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Mar 22 13:18:51 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958281, encodeId=34dc95828114, content=毫无疑问,出国的,医护人员 , beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ZJYYY7, createdTime=Mon Apr 19 11:59:08 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029380, encodeId=a95a1029380e0, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036573, encodeId=668610365e315, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-04-19 ZJYYY7

    毫无疑问,出国的,医护人员

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1734350, encodeId=bed41e343504c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jan 11 13:18:51 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728908, encodeId=d3441e2890865, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 08 20:18:51 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717067, encodeId=a8f51e170670f, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Mar 22 13:18:51 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958281, encodeId=34dc95828114, content=毫无疑问,出国的,医护人员 , beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ZJYYY7, createdTime=Mon Apr 19 11:59:08 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029380, encodeId=a95a1029380e0, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036573, encodeId=668610365e315, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-04-14 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1734350, encodeId=bed41e343504c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Jan 11 13:18:51 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728908, encodeId=d3441e2890865, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat May 08 20:18:51 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717067, encodeId=a8f51e170670f, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Mar 22 13:18:51 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958281, encodeId=34dc95828114, content=毫无疑问,出国的,医护人员 , beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ZJYYY7, createdTime=Mon Apr 19 11:59:08 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029380, encodeId=a95a1029380e0, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036573, encodeId=668610365e315, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 14 14:18:51 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-04-14 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

NEJM:国药和科兴疫苗对突变株中和效力数据发布,再次证实病毒变异监测重要性

4月7日,《新英格兰医学》发表来自中国军事医学科学院微生物流行病研究所以及德州疾控中心等单位通讯文章,阐述了两款国产疫苗,即BBIBP-CorV [国药]或克尔来福[科兴]疫苗对B.1.1.7和B.1

强生疫苗或导致血栓,腺病毒载体疫苗还安全吗?

欧洲药品监管机构表示,正在审查四名接种强生新冠疫苗的人中出现的罕见血凝块的报道

阿斯利康新冠疫苗防护效力达79%,未发现严重血栓事件

今日,阿斯利康公布了其与牛津大学联合开发的新冠疫苗AZD1222的Ⅲ期临床试验中期分析结果。

为什么中国考虑年轻人优先接种新冠疫苗?

科学决定如何接种至关重要。

2021年4月10日全球新冠肺炎(COVID-19)疫情简报,确诊超1亿3526万,我国疫苗接种超过1.55亿剂次

Worldometers世界实时统计数据显示,截至北京时间2021年4月10日7时01分,全球累计确诊新冠肺炎(COVID-19)病例超过13526万例,新增760,680例,达到135,264,65

科兴灭活疫苗巴西三期临床试验结果出炉!

导语:国产新冠疫苗里科兴第一个完整披露三期临床试验结果,此前进展也一直排在全球新冠疫苗研发前列。